February 2021 Simoa® Publications:
Other Research Areas: Oncology, Inflammation, Infectious Disease, RPPA Technology, and more
A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy
Choueiri, T. K, et al.
Invest New Drugs (2021)
Oncology
Distinct profile of CD34(+) cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive disease
Forte D, et al.
J Exp Clin Cancer Res 40, 49 (2021).
Oncology
JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study
Voyer, TL, et al.
Rheumatology, keab116
Inflammation
Dietary saturated fatty acid palmitate promotes cartilage lesions and activates the unfolded protein response pathway in mouse knee joints
Tan, L, et al.
PLoS One. 2021;16:e0247237
Inflammation
Upregulation of IL-15 in the placenta alters trophoblasts behavior contributing to gestational diabetes mellitus
Li, J, et al.
Cell Biosci. 2021;11:33
Inflammation
Ubiquitin Ligase SMURF2 Interacts with Filovirus VP40 and Promotes Egress of VP40 VLPs
Shepley-McTaggart, A, et al.
Viruses. 2021;13:288
Infectious Disease
Plasma Exchange to Rescue Patients with Autoantibodies Against Type I Interferons and Life-Threatening COVID-19 Pneumonia
de Prost, N, et al.
J Clin Immunol. 2021:1-9
Infectious Disease
Reverse-Phase Protein Array: Technology, Application, Data Processing, and Integration
Coarfa, C, et al.
J Biomol Tech. 2021 Jan 15;jbt.2021-3202-001
RPPA Technology
Characterization of Signalling Pathways That Link Apoptosis and Autophagy to Cell Death Induced by Estrone Analogues Which Reversibly Depolymerize Microtubules
Mercier, AE, et al.
Molecules 2021, 26(3), 706
February 2021 Simoa® Publications in Other Therapeutic Areas
